CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

While Casgevy is currently the only CRISPR-based therapy, several companies are advancing gene-editing treatments using similar technology. Beam Therapeutics BEAM is developing its lead candidate ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. See why CRSP stock is a Hold.

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

That means Casgevy will be covered “immediately” by the IMF to speed up the rollout for up to 460 people eligible for the treatment, according to NICE. The drug carries a list price of ...

As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already ...

The Food and Drug Administration (FDA) has approved Casgevy ™ (exagamglogene autotemcel) for the treatment of patients aged 12 years and older with transfusion-dependent β-thalassemia (TDT).

The other, Casgevy, genetically edits stem cells to do the same. Casgevy is a therapy based on CRISPR, which stands for "clustered regularly interspaced short palindromic repeats." ...